Ipsen SA – Strategy, SWOT and Corporate Finance Report
- Pages: 59
- Published: April 2019
- Report Code: MLPH15876FSA
Ipsen SA – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360Ëš view of the company.
Ipsen SA (Ipsen) is a global specialty biopharmaceutical company that manufactures and distributes drugs for the treatment of cancer and rare and neurological diseases. The company develops and commercializes novel medicines in cancer, neuroscience and rare diseases. It also offers products to treat gastrointestinal disorders, neurodegenerative pathologies and rheumatology diseases. Ipsen sells its drugs through distributors and directly to hospitals in some countries. It has research and development (R&D) facilities in Paris-Saclay, France; Oxford, the UK; and Cambridge, the US. The company provides products in Europe, North America, Asia and rest of the world. Ipsen is headquartered in Paris, France.
Scope
Detailed information on Ipsen SA required for business and competitor intelligence needs
A study of the major internal and external factors affecting Ipsen SA in the form of a SWOT analysis
An in-depth view of the business model of Ipsen SA including a breakdown and examination of key business segments
News about Ipsen SA, such as business expansion, restructuring, and contract wins
Large number of easy-to-grasp charts and graphs that present important data and key trends
Reasons to buy
Gain understanding of Ipsen SA and the factors that influence its strategies.Track strategic initiatives of the company and latest corporate news and actions.
Assess Ipsen SA as a prospective partner, vendor or supplier.
Support sales activities by understanding your customers' businesses better.
Stay up to date on Ipsen SAs business structure, strategy and prospects.
Note: Some sections may be missing if data is unavailable for the company.
Companies mentioned
UCB Pharma SA
Sanofi
OSE Immunotherapeutics
Onxeo SA
Mylan NV
Laboratoires Pierre Fabre SA
GlaxoSmithKline Plc
Genfit SA
Fareva SA
Eurofins Cerep SA
Avadel Pharmaceuticals Plc
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.